M
Matyas Ecsedi
Researcher at University Hospital of Basel
Publications - 8
Citations - 480
Matyas Ecsedi is an academic researcher from University Hospital of Basel. The author has contributed to research in topics: T cell & Transplantation. The author has an hindex of 3, co-authored 5 publications receiving 396 citations.
Papers
More filters
Journal ArticleDOI
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
Robert Zeiser,Andreas Burchert,Claudia Lengerke,Mareike Verbeek,Kristina Maas-Bauer,S K Metzelder,Silvia Spoerl,Markus Ditschkowski,Matyas Ecsedi,Katja Sockel,Francis Ayuk,Salem Ajib,F.S. de Fontbrune,Il-Kang Na,Livius Penter,Udo Holtick,Dominik Wolf,Esther Schuler,Everett Meyer,Petya Apostolova,Hartmut Bertz,Reinhard Marks,Michael Lübbert,Ralph Wäsch,Christoph Scheid,Friedrich Stölzel,Rainer Ordemann,Gesine Bug,Guido Kobbe,Robert S. Negrin,Mats Brune,Alexandros Spyridonidis,Annette Schmitt-Gräff,W.J.F.M. van der Velden,Gerwin Huls,Stephan Mielke,G. U. Grigoleit,Jürgen Kuball,Ryan Flynn,Gabriele Ihorst,Jing Du,Bruce R. Blazar,Renate Arnold,Kröger N,Jakob Passweg,Jörg Halter,Gérard Socié,Dietrich W. Beelen,Christian Peschel,Andreas Neubauer,Jürgen Finke,Justus Duyster,N von Bubnoff +52 more
TL;DR: Ruxolitinib may constitute a promising new treatment option for SR-aGVHD and SR-cGVHD that should be validated in a prospective trial.
Journal ArticleDOI
Use of eltrombopag in aplastic anemia in Europe
Matyas Ecsedi,Etienne Lengliné,Cora Knol-Bout,Paul Bosman,Dirk-Jan Eikema,Boris V. Afanasyev,Alexei Maschan,Peter Dreger,Constantijn J. M. Halkes,Beatrice Drexler,Agostino Cortelezzi,Bernard Drenou,Andrea Patriarca,Benedetto Bruno,Daniela Onofrillo,Edoardo Lanino,Drazen Pulanic,Ranka Serventi-Seiwerth,Alice Garnier,Per Ljungman,Francesca Bonifazi,Sabrina Giammarco,Olivier Tournilhac,Pietro Pioltelli,Alicia Rovó,Antonio M. Risitano,Régis Peffault de Latour,Carlo Dufour,Jakob Passweg +28 more
TL;DR: Eltrombopag is used widely in Europe to treat AA patients, mostly in the relapsed/refractory setting, and response to ELT is similar to the clinical trial data across different age groups, treatment lines, and treatment combinations and results in favorable survival.
Journal ArticleDOI
Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib
Robert Zeiser,Andreas Burchert,Claudia Lengerke,Mareike Verbeek,Kristina Maas-Bauer,S K Metzelder,Silvia Spoerl,Markus Ditschkowski,Matyas Ecsedi,Katja Sockel,Francis Ayuk,Ajib Salem,Flore Sicre de Fontbrune,Il-Kang Na,Penter Livius,Udo Holtick,Dominik Wolf,Esther Schuler,Everett Meyer,Petya Apostolova,Hartmut Bertz,Reinhard Marks,Michael Lübbert,Ralph Wäsch,Christof Scheid,Friedrich Stölzel,Rainer Ordemann,Gesine Bug,Guido Kobbe,Omid Shah,Robert S. Negrin,Mats Brune,Alexandros Spyridonidis,Annette Schmitt-Graeff,Walter J.F.M. van der Velden,Gerwin Huls,Stephan Mielke,Goetz Ulrich Grigoleit,Jürgen Kuball,Ryan Flynn,Gabriele Ihorst,Jing Du,Bruce R. Blazar,Renate Arnold,Nicolaus Kröger,Jakob Passweg,Joerg Halter,Gérard Socié,Dietrich W. Beelen,Christian Peschel,Andreas Neubauer,Jürgen Finke,Justus Duyster,Nikolas von Bubnoff +53 more
TL;DR: It is shown that patients with SR-aGVHD and SR-cGVHD may benefit long-term from ruxolitinib treatment with an OS that is relatively high for steroid-refractory GVHD.
Journal ArticleDOI
Anti-thymocyte globulin-induced hyperbilirubinemia in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation.
Matyas Ecsedi,Jörg Schmohl,Robert Zeiser,Beatrice Drexler,Jörg Halter,Michael Medinger,Justus Duyster,Lothar Kanz,Jakob Passweg,Jürgen Finke,Wolfgang Bethge,Claudia Lengerke +11 more
TL;DR: awareness of this stereotypic bilirubin elevation in MF patients treated with ATG provides a relatively benign explanation for hyperbilirubinemia occurring in these patients during the early transplant, but attention to drug levels of biliary excreted drugs is warranted.
Journal ArticleDOI
Treatment of Corticosteroid-Refractory Graft-Versus-Host Disease with Ruxolitinib in 95 Patients
Robert Zeiser,Andreas Burchert,Claudia Lengerke,Mareike Verbeek,Kristina Maas-Bauer,S K Metzelder,Silvia Spoerl,Markus Ditschkowski,Matyas Ecsedi,Katja Sockel,Francis Ayuk,Salem Ajib,Flore Sicre de Fontbrune,Il-Kang Na,Livius Penter,Udo Holtick,Dominik Wolf,Esther Schuler,Everett Meyer,Petya Apostolova,Hartmut Bertz,Reinhard Marks,Michael Luebbert,Ralph Waesch,Christof Scheid,Friedrich Stölzel,Rainer Ordemann,Gesine Bug,Guido Kobbe,Robert S. Negrin,Mats Brune,Alexandros Spyridonidis,Annette Schmitt-Graeff,Walter J.F.M. van der Velden,Gerwin Huls,Stephan Mielke,Goetz Ulrich Grigoleit,Jürgen Kuball,Ryan Flynn,Gabriele Ihorst,Jing Du,Bruce R. Blazar,Renate Arnold,Nicolaus Kröger,Joerg Halter,Gérard Socié,Dietrich W. Beelen,Christian Peschel,Andreas Neubauer,Juergen Finke,Justus Duyster,Nikolas von Bubnoff +51 more
TL;DR: Ruxolitinib constitutes a promising new treatment option for SR-aGVHD and SR-cGVHD, and should be validated in a prospective trials in both,SR-aGvHD and cGVHD.